Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

被引：24
|
作者：
Valle, JW
Dangoor, A
Beech, J
Sherlock, DJ
Lee, SM
Scarffe, JH
Swindell, R
Ranson, M
机构：
[1] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[2] N Manchester Grp Hosp, Pennine Acute Hosp NHS Trust, Manchester M8 5RB, Lancs, England
[3] Middlesex Hosp, London W1T 3AA, England
[4] Lister Hosp, E&N Herts NHS Trust, Stevenage SG1 4AB, Herts, England
来源：
BRITISH JOURNAL OF CANCER | 2005年 / 92卷 / 04期
关键词：
pegylated liposomal doxorubicin; hepatocellular carcinoma; phase II;
D O I：
10.1038/sj.bjc.6602394
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(-2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.
引用
收藏
页码：628 / 630
页数：3
相关论文
共 50 条
  • [21] Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study
    Rozzi, Antonio
    Santini, Daniele
    Salerno, Margherita
    Bordin, Francesca
    Mancuso, Andrea
    Minniti, Giuseppe
    Nardoni, Chiara
    Corona, Michela
    Falbo, Pina Tiziana
    Recine, Federica
    Lanzetta, Gaetano
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [22] Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone
    Krasner, Carolyn N.
    Poveda, Andres
    Herzog, Thomas J.
    Vermorken, Jan B.
    Kaye, Stanley B.
    Nieto, Antonio
    Lardelli Claret, Pilar
    Park, Youn Choi
    Parekh, Trilok
    Monk, Bradley J.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (01) : 161 - 167
  • [23] Phase II Study of Neoadjuvant Gemcitabine, Pegylated Liposomal Doxorubicin, and Docetaxel in Locally Advanced Breast Cancer
    Grazia, Artioli
    Simone, Mocellin
    Lucia, Borgato
    Alessandro, Cappetta
    Fernando, Bozza
    Giorgio, Zavagno
    Stefania, Zovato
    Alberto, Marchet
    Davide, Pastorelli
    ANTICANCER RESEARCH, 2010, 30 (09) : 3817 - 3821
  • [24] A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer
    Recchia, Francesco
    Saggio, Gaetano
    Amiconi, Giovanna
    Di Blasio, Anna
    Cesta, Alisia
    Candeloro, Giampiero
    Carta, Gaspare
    Necozione, Stefano
    Mantovani, Giovanni
    Rea, Silvio
    GYNECOLOGIC ONCOLOGY, 2007, 106 (01) : 164 - 169
  • [25] Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer
    Nicoletto, MO
    Falci, C
    Pianalto, D
    Artioli, G
    Azzoni, P
    De Masi, G
    Ferrazzi, E
    Perin, A
    Donach, M
    Zoli, W
    GYNECOLOGIC ONCOLOGY, 2006, 100 (02) : 318 - 323
  • [26] Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours
    Caraglia, M
    Addeo, R
    Costanzo, R
    Montella, L
    Faiola, V
    Marra, M
    Abbruzzese, A
    Palmieri, G
    Budillon, A
    Grillone, F
    Venuta, S
    Tagliaferri, P
    Del Prete, S
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (01) : 34 - 39
  • [27] Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours
    Michele Caraglia
    Raffaele Addeo
    Raffaele Costanzo
    Liliana Montella
    Vincenzo Faiola
    Monica Marra
    Alberto Abbruzzese
    Giovannella Palmieri
    Alfredo Budillon
    Francesco Grillone
    Salvatore Venuta
    Pierosandro Tagliaferri
    Salvatore Del Prete
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 34 - 39
  • [28] Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study
    Hong, RL
    Tseng, YL
    Chang, FH
    ANNALS OF ONCOLOGY, 2000, 11 (03) : 349 - 353
  • [29] A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
    Jonas, Brian A.
    Potter, Laura A.
    Galkin, Maria
    Tuscano, Joseph M.
    LEUKEMIA RESEARCH REPORTS, 2023, 19
  • [30] Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: A phase II study
    Power, Patti
    Stuart, Gavin
    Oza, Amit
    Provencher, D.
    Bentley, James R.
    Miller, Wilson H., Jr.
    Pouliot, Jean-Francois
    GYNECOLOGIC ONCOLOGY, 2009, 114 (03) : 410 - 414
12345